![Caterina Menichelli](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Caterina Menichelli currently works at Bactobio Ltd., as Head-Operations.
Actieve functies van Caterina Menichelli
Bedrijven | Functie | Begin |
---|---|---|
Bactobio Ltd.
![]() Bactobio Ltd. BiotechnologyHealth Technology Bactobio Ltd. is a biotechnology company based in an undisclosed location. The British company uses synthetic biology, next-generation sequencing, and machine learning to cultivate previously unculturable microbes. Bactobio has exclusive access to a large bioresource, which allows them to discover novel chemical and biological products in the pharmaceutical, agricultural, and bioderived-chemical sectors. The company's first goal is to help solve the growing antimicrobial resistance crisis. Bactobio has developed a platform to culture soil bacteria that have not been culturable in the laboratory and uncover valuable secondary metabolites they produce. The company's proprietary technology combines microbiology with bioinformatics and machine learning to expand access to novel species with the potential to produce solutions across healthcare, agriculture, and industrial markets. The company was founded in 2020 by Andreas Harris and Daniel Hansen, with Daniel Hansen serving as CEO since then. | Operationeel Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Bactobio Ltd.
![]() Bactobio Ltd. BiotechnologyHealth Technology Bactobio Ltd. is a biotechnology company based in an undisclosed location. The British company uses synthetic biology, next-generation sequencing, and machine learning to cultivate previously unculturable microbes. Bactobio has exclusive access to a large bioresource, which allows them to discover novel chemical and biological products in the pharmaceutical, agricultural, and bioderived-chemical sectors. The company's first goal is to help solve the growing antimicrobial resistance crisis. Bactobio has developed a platform to culture soil bacteria that have not been culturable in the laboratory and uncover valuable secondary metabolites they produce. The company's proprietary technology combines microbiology with bioinformatics and machine learning to expand access to novel species with the potential to produce solutions across healthcare, agriculture, and industrial markets. The company was founded in 2020 by Andreas Harris and Daniel Hansen, with Daniel Hansen serving as CEO since then. | Health Technology |